Contact Us
Drug Search Results
More Filters [+]

NG-350A

Alternative Names: ng-350A, ng350A, ng 350A, ng-350a, ng 350a, ng350a
Latest Update: 2024-12-17
Latest Update Note: News Article

Product Description

NG-350A is being developed by PsiOxus for the treatment of patients with Epithelial Tumor and Metastatic Cancer. (Sourced from: https://clinicaltrials.gov/ct2/show/NCT05165433?term=NG-350A&draw=2&rank=1)

Mechanisms of Action: CD40 Agonist

Novel Mechanism: Yes

Modality: Antibody

Route of Administration: Intravenous

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Akamis Bio
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for NG-350A

Countries in Clinic: United Kingdom, United States

Active Clinical Trial Count: 3

Highest Development Phases

Phase 1: Colorectal Cancer|Oncology Solid Tumor Unspecified

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
FORTRESS

P1

Not yet recruiting

Colorectal Cancer

2026-02-28

FORTIFY

P1

Active, not recruiting

Oncology Solid Tumor Unspecified

2025-03-17

FORTITUDE

P1

Completed

Oncology Solid Tumor Unspecified

2022-02-04

34%

Recent News Events

Date

Type

Title

12/17/2024

News Article

 Akamis Bio Announces $60 Million in Funding Linked to Series A Prime Financing and New Strategic Partnership

10/23/2024

News Article

 Akamis Bio Announces Publication Detailing Initial Proof of Mechanism for NG-350A, an IV-Dosed Tumor Gene Therapy Delivering a CD40 Agonist Payload

10/03/2023

News Article

 Akamis Bio Highlights Data Showing Potential of its Adenovirus Vector Technology in Combination with Radiation to Treat Advanced Rectal Cancer

07/06/2023

News Article

 Akamis Bio Strengthens Leadership Team with Key Executive Appointments

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions